Vetiqure AB is a wholly owned subsidiary of Scandinavian ChemoTech AB, a dynamic Life Science company that focus on developing technologies and therapies for various cancer tumours and advanced pain control for cancer. The Company has extensive experience in Tumour Specifik Electroporation™ (TSE), which forms the basis of the Company’s therapeutic areas. Currently, the Company is offering treatments for a various forms of cancer tumours. The Company is based at Medicon Village in Lund, Sweden.
Following extensive research and development, Vetiqure AB recently launched the vetIQure™ device. With its new patented technology, TSE (Tumour Specific Electroporation), it offers gentle yet effective and flexible treatments capabilities. vetIQure™ has been designed to achieve positive clinical outcomes on a level previously not possible. vetIQure™, is designed for animals based on a technology developed to treat humans. TSE makes it possible to treat non-responsive tumours and tumours in sensitive locations. Read more»
vetIQure™ has now been launched and introduced to the veterinarian market and we are looking forward to close collaborations with both customers and distributors in Europe and the rest of the world.